Using Imipenem and Cilastatin During Continuous Renal Replacement Therapy

Author： Cotton Alison   Franklin Bryony   Brett Stephen   Holmes Alison  

Publisher： Springer Publishing Company

ISSN： 0928-1231

Source： Pharmacy World and Science, Vol.27, Iss.5, 2005-10, pp. : 371-375

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug Dosing During Intermittent Hemodialysis and Continuous Renal Replacement Therapy: Special Considerations in Pediatric Patients

By Veltri M.A.  

Pediatric Drugs, Vol. 6, Iss. 1, 2004-01 ,pp. : 45-65

Adis International

Access to resources Recommend Favorite

Safety of arteriovenous fistulae and grafts for continuous renal replacement therapy: The Michigan experience

By  

Hemodialysis International, Vol. 22, Iss. 1, 2018-01 ,pp. : 50-55

John Wiley & Sons Inc

Access to resources Recommend Favorite

Imipenem/cilastatin: Drug hypersensitivity: case report

By  

Reactions Weekly, Vol. 1, Iss. 1169, 2007-01 ,pp. : 17-18

Adis International

Access to resources Recommend Favorite

Management of Heparin‐Induced Thrombocytopenia During Renal Replacement Therapy

By  

Hemodialysis International, Vol. 5, Iss. 1, 2001-01 ,pp. : 81-85

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population Pharmacokinetics of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy

By Isla Arantxazu  

Clinical Pharmacokinetics, Vol. 47, Iss. 3, 2008-01 ,pp. : 173-180

Adis International

Access to resources Recommend Favorite